Pacira BioSciences, Company Insiders
PCRX Stock | USD 24.14 0.32 1.34% |
Slightly above 80 percent of Pacira BioSciences,'s insiders are selling. The analysis of insiders' sentiment of trading Pacira BioSciences, stock suggests that a fairly large number of insiders are terrified at this time. Pacira BioSciences, employs about 788 people. The company is managed by 18 executives with a total tenure of roughly 38 years, averaging almost 2.0 years of service per executive, having 43.78 employees per reported executive.
David Stack Chairman Chairman and CEO |
Insider Sentiment 20
Mostly Selling
Selling | Buying |
Latest Trades
2025-01-06 | Jonathan Slonin | Disposed 879 @ 18.4 | View | ||
2024-12-13 | Daryl Gaugler | Disposed 500 @ 19.76 | View | ||
2024-09-13 | Daryl Gaugler | Disposed 500 @ 12.86 | View | ||
2024-08-16 | Marcelo Bigal | Acquired 1512 @ 13.25 | View | ||
2024-08-12 | Mark Froimson | Acquired 1400 @ 11.58 | View | ||
2024-08-02 | Jonathan Slonin | Disposed 945 @ 20.05 | View | ||
2024-07-02 | Jonathan Slonin | Disposed 2836 @ 28.25 | View | ||
2024-06-13 | Paul J Hastings | Disposed 880 @ 28.38 | View | ||
2024-06-12 | Lauren Riker | Disposed 3970 @ 28.72 | View | ||
2024-06-11 | Jonathan Slonin | Disposed 5012 @ 28.57 | View |
Monitoring Pacira BioSciences,'s insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Pacira |
Pacira BioSciences,'s Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Pacira BioSciences,'s future performance. Based on our forecasts, it is anticipated that Pacira will maintain a workforce of slightly above 790 employees by April 2025.Pacira BioSciences, Management Team Effectiveness
The company has return on total asset (ROA) of 0.039 % which means that it generated a profit of $0.039 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1208) %, meaning that it created substantial loss on money invested by shareholders. Pacira BioSciences,'s management efficiency ratios could be used to measure how well Pacira BioSciences, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.09 in 2025. Return On Capital Employed is likely to drop to -0.06 in 2025. At this time, Pacira BioSciences,'s Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 241.3 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 414.1 M in 2025.Net Income Applicable To Common Shares is likely to rise to about 19.2 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 36.8 M in 2025.
Pacira BioSciences, Workforce Comparison
Pacira BioSciences, is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 34,763. Pacira BioSciences, holds roughly 788 in number of employees claiming about 2.27% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.16 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.16. Pacira BioSciences, Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacira BioSciences, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacira BioSciences,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pacira BioSciences, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 1.5 | 6 | 4 | 706,900 | 10,784 |
2024-12-01 | 3.0 | 3 | 1 | 275,244 | 500.00 |
2024-09-01 | 1.2 | 6 | 5 | 17,576 | 5,500 |
2024-06-01 | 2.5 | 25 | 10 | 353,759 | 30,516 |
2024-03-01 | 1.5 | 6 | 4 | 874,432 | 119,482 |
2023-12-01 | 0.6667 | 4 | 6 | 123,868 | 111,937 |
2023-06-01 | 0.7436 | 29 | 39 | 583,200 | 126,821 |
2022-06-01 | 0.9167 | 44 | 48 | 827,110 | 334,126 |
2022-03-01 | 0.6512 | 28 | 43 | 157,922 | 248,193 |
2021-12-01 | 0.1765 | 3 | 17 | 32,500 | 158,075 |
2021-09-01 | 0.75 | 6 | 8 | 32,500 | 57,058 |
2021-06-01 | 1.3448 | 39 | 29 | 433,909 | 175,751 |
2021-03-01 | 0.2222 | 6 | 27 | 46,520 | 387,484 |
2020-12-01 | 0.25 | 5 | 20 | 100,000 | 445,000 |
2020-09-01 | 0.3846 | 15 | 39 | 164,404 | 599,326 |
2020-06-01 | 1.5556 | 42 | 27 | 1,160,846 | 186,637 |
2020-03-01 | 0.8 | 12 | 15 | 92,828 | 109,200 |
2019-12-01 | 0.5769 | 15 | 26 | 97,448 | 209,674 |
2019-09-01 | 0.5 | 5 | 10 | 246,768 | 72,180 |
2019-06-01 | 2.0 | 36 | 18 | 556,007 | 87,312 |
2018-12-01 | 0.4211 | 8 | 19 | 66,500 | 223,738 |
2018-09-01 | 0.2 | 5 | 25 | 36,091 | 272,866 |
2018-06-01 | 1.9333 | 29 | 15 | 489,700 | 114,466 |
2018-03-01 | 0.5 | 2 | 4 | 88,885 | 57,770 |
2017-12-01 | 0.4167 | 5 | 12 | 68,770 | 196,730 |
2017-09-01 | 0.6 | 3 | 5 | 43,985 | 77,275 |
2017-06-01 | 1.56 | 39 | 25 | 509,182 | 209,144 |
2017-03-01 | 0.4286 | 3 | 7 | 35,000 | 70,000 |
2016-12-01 | 1.8333 | 11 | 6 | 233,000 | 100,000 |
2016-09-01 | 0.6 | 3 | 5 | 40,000 | 80,000 |
2016-06-01 | 3.0 | 30 | 10 | 412,491 | 54,574 |
2016-03-01 | 1.0 | 7 | 7 | 21,800 | 36,000 |
2015-12-01 | 0.5 | 3 | 6 | 58,000 | 36,000 |
2015-09-01 | 1.25 | 5 | 4 | 138,000 | 36,000 |
2015-06-01 | 5.5 | 22 | 4 | 109,250 | 55,000 |
2015-03-01 | 0.4 | 8 | 20 | 64,849 | 119,349 |
2014-12-01 | 0.3333 | 7 | 21 | 37,225 | 138,041 |
2014-09-01 | 0.4 | 14 | 35 | 583,500 | 894,007 |
2014-06-01 | 0.625 | 20 | 32 | 467,000 | 501,900 |
2014-03-01 | 1.0 | 4 | 4 | 16,725 | 26,887 |
2013-12-01 | 0.6 | 9 | 15 | 97,997 | 195,000 |
2013-09-01 | 0.3636 | 12 | 33 | 216,987 | 729,193 |
2013-06-01 | 0.375 | 24 | 64 | 263,853 | 1,733,974 |
2013-03-01 | 0.4167 | 25 | 60 | 630,143 | 8,742,900 |
2012-03-01 | 0.4063 | 13 | 32 | 8,237,883 | 7,122,644 |
2011-12-01 | 3.5 | 7 | 2 | 2,017,690 | 97,441 |
2011-06-01 | 3.0 | 6 | 2 | 71,384 | 0.00 |
2011-03-01 | 1.64 | 82 | 50 | 27,986,922 | 21,650,746 |
Pacira BioSciences, Notable Stakeholders
A Pacira BioSciences, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pacira BioSciences, often face trade-offs trying to please all of them. Pacira BioSciences,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pacira BioSciences,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Frank Lee | CEO Director | Profile | |
David Stack | Chairman and CEO | Profile | |
Richard Kahr | Vice Resources | Profile | |
Daryl Gaugler | Chief Officer | Profile | |
Charles Laranjeira | Chief Technical Officer | Profile | |
Christopher Young | Chief Officer | Profile | |
Shawn Cross | Chief Officer | Profile | |
JD Esq | Chief Secretary | Profile | |
DO Ellis | Chief Officer | Profile | |
III CPA | Chief Officer | Profile | |
Max Reinhardt | Pres World | Profile | |
Dennis McLoughlin | Chief Commercial Officer | Profile | |
Kristen JD | Chief Secretary | Profile | |
Roy MD | Chief Officer | Profile | |
Susan Mesco | IR Contact Officer | Profile | |
Jonathan MD | Chief Officer | Profile | |
Lauren Riker | Principal Finance | Profile | |
Esq III | Chief Officer | Profile |
About Pacira BioSciences, Management Performance
The success or failure of an entity such as Pacira BioSciences, often depends on how effective the management is. Pacira BioSciences, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pacira management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pacira management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.09) | (0.09) | |
Return On Capital Employed | (0.06) | (0.06) | |
Return On Assets | (0.06) | (0.07) | |
Return On Equity | (0.13) | (0.13) |
Please note, the imprecision that can be found in Pacira BioSciences,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pacira BioSciences,. Check Pacira BioSciences,'s Beneish M Score to see the likelihood of Pacira BioSciences,'s management manipulating its earnings.
Pacira BioSciences, Workforce Analysis
Traditionally, organizations such as Pacira BioSciences, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pacira BioSciences, within its industry.Pacira BioSciences, Manpower Efficiency
Return on Pacira BioSciences, Manpower
Revenue Per Employee | 889.6K | |
Revenue Per Executive | 38.9M | |
Net Loss Per Employee | 126.3K | |
Net Loss Per Executive | 5.5M | |
Working Capital Per Employee | 552.3K | |
Working Capital Per Executive | 24.2M |
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.